EMA Opens Registration for European Network of Paediatric Research Workshop
EMA opens registration for it's sixth annual workshop on pediatric drug research and development.
The European Medicines Agency (EMA) has begun registration for its sixth workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). The workshop will take place at EMA’s headquarters in London on June 26-27, 2014. The workshop, which aims to strengthen communication between stakeholders, will update participants from all aspects of the industry on “Enpr-EMA’s efforts to foster high-quality paediatric drug research and to contribute to the ongoing development of research and clinical trials in the area of paediatric medicine.”
Enpr-EMA, which is comprised by a network of research networks, investigators, and centers with expertise in performing clinical studies in children, fosters ethical research on the quality, safety and efficacy of medicines for use in children; helps recruit patients for clinical trials, and creates collaboration between networks.
Workshop registration forms can be found on EMA’s website) and should be submitted to enprema@ema.europa.eu.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
